AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18241137 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 0
Study 15987669 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-naïve patients
Number of subjects: 80
Study 15987669 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventionally treated patients (haloperidol or fluphenazine)
Number of subjects: 80
Study 15987669 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypically treated patients (olanzapine)
Number of subjects: 80
Study 15987669 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 80
Study 15987669 — intervention group
Group type: EXPERIMENTAL
Intervention: All patient groups
Number of subjects: 80
Study 15987669 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventionally treated patients
Number of subjects: 80
Study 15987669 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypically and conventionally treated patients
Number of subjects: 80
Study 15987669 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-naïve and treated patients
Number of subjects: 80
Study 12453256 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin modified glass-ionomer (Vitremer)
Number of subjects: 24
Study 12453256 — intervention group
Group type: COMPARATOR
Intervention: Composite resin (Z100)
Number of subjects: 24
Study 9920948 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg) plus methotrexate
Number of subjects: 89
Study 9920948 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate
Number of subjects: 89
Study 9208666 — intervention group
Group type: EXPERIMENTAL
Intervention: Madopar treatment (26 amblyopia eyes)
Number of subjects: 314
Study 9208666 — intervention group
Group type: COMPARATOR
Intervention: Amblyopia eyes (108 amblyopia eyes)
Number of subjects: 314
Study 2127054 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha‐interferon
Number of subjects: 115
Study 7356903 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg cimetidine with 250 mg tetracycline tablets
Number of subjects: 6
Study 7356903 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 250 mg tetracycline tablets
Number of subjects: 6
Study 7356903 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg cimetidine 8 hourly for 6 days with 500 mg tetracycline as tablets
Number of subjects: 6
Study 7356903 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 500 mg tetracycline as suspension
Number of subjects: 6
Study 7356903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine treatment
Number of subjects: 6
Study 7356903 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline tablets and suspension
Number of subjects: 6
Study 30820770 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined event files
Number of subjects: 0
Study 30820770 — intervention group
Group type: COMPARATOR
Intervention: Perceived event files
Number of subjects: 0
Study 29511316 — intervention group
Group type: EXPERIMENTAL
Intervention: n-back training with strategy instruction
Number of subjects: 116
Study 29511316 — intervention group
Group type: EXPERIMENTAL
Intervention: n-back training without strategy instruction
Number of subjects: 116
Study 29511316 — intervention group
Group type: COMPARATOR
Intervention: Passive controls
Number of subjects: 116
Study 26227922 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-articular injections (PAI)
Number of subjects: 80
Study 26227922 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 80
Study 24668608 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% glucose solution
Number of subjects: 12
Study 24668608 — intervention group
Group type: COMPARATOR
Intervention: 0.05% aspartame solution
Number of subjects: 12
Study 24668608 — intervention group
Group type: COMPARATOR
Intervention: 9.0% maltodextrin solution
Number of subjects: 12
Study 24668608 — intervention group
Group type: COMPARATOR
Intervention: water
Number of subjects: 12
Study 22928884 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% oral glucose
Number of subjects: 11
Study 22928884 — intervention group
Group type: COMPARATOR
Intervention: Nothing (control)
Number of subjects: 11
Study 20350322 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined diabetes knowledge/information and motivation/behavioral skills training intervention
Number of subjects: 232
Study 20350322 — intervention group
Group type: COMPARATOR
Intervention: Usual care/general health education group
Number of subjects: 232
Study 17885013 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention group
Number of subjects: 3088
Study 15987428 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy (1 mg/day of micronized 17beta‐estradiol)
Number of subjects: 232
Study 15987428 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined estrogen and progestin therapy (17beta‐estradiol and 5 mg/day of medroxyprogesterone acetate for 12 days/month)
Number of subjects: 232
Study 15987428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 12085073 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured skills-based intervention (4-hour didactic, video, and skills-based workshop)
Number of subjects: 36
Study 12085073 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study 9464197 — intervention group
Group type: EXPERIMENTAL
Intervention: Short REM latency in relatives of depressed probands with short REM latency
Number of subjects: 252
Study 9464197 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime risk of depression in relatives of depressed probands with short REM latency
Number of subjects: 252
Study 9464197 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnographic abnormalities in unaffected relatives
Number of subjects: 252
Study 7842768 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 micrograms ipratropium bromide plus 200 micrograms salbutamol
Number of subjects: 26
Study 7842768 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 micrograms ipratropium bromide plus 400 micrograms salbutamol
Number of subjects: 26
Study 7842768 — intervention group
Group type: COMPARATOR
Intervention: 80 micrograms ipratropium bromide
Number of subjects: 26
Study 7842768 — intervention group
Group type: COMPARATOR
Intervention: 40 micrograms ipratropium bromide
Number of subjects: 26
Study 7842768 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms salbutamol and 40 micrograms ipratropium bromide
Number of subjects: 26
Study 2404204 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (2.5 mg per kilogram of body weight per day)
Number of subjects: 73
Study 2404204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 361408 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 39
Study 361408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 31806052 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression therapy (group A)
Number of subjects: 0
Study 31806052 — intervention group
Group type: COMPARATOR
Intervention: No compression (group B)
Number of subjects: 0
Study 29369237 — intervention group
Group type: EXPERIMENTAL
Intervention: sEGD
Number of subjects: 201
Study 29369237 — intervention group
Group type: COMPARATOR
Intervention: huTNE
Number of subjects: 201
Study 29369237 — intervention group
Group type: COMPARATOR
Intervention: muTNE
Number of subjects: 201
Study 27697943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (Smoke Free Homes Program)
Number of subjects: 508
Study 27697943 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 508
Study 24946646 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted-electroacupuncture
Number of subjects: 80
Study 22000747 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiochemotherapy with radiation doses of 50.4 Gy combined with 5-fluorouracil-based chemotherapy
Number of subjects: 163
Study 20153888 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg orally twice daily
Number of subjects: 3381
Study 20153888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3381
Study 17284556 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline resilience (low burden, high care demands)
Number of subjects: 1979
Study 16184258 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg
Number of subjects: 0
Study 16184258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12722936 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 adjunctive hypnosis sessions targeting accelerated wound healing
Number of subjects: 18
Study 12722936 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 adjunctive supportive attention sessions
Number of subjects: 18
Study 12722936 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 18
Study 10802311 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-insulin
Number of subjects: 0
Study 10802311 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-glucose
Number of subjects: 0
Study 10802311 — intervention group
Group type: COMPARATOR
Intervention: CS-placebo
Number of subjects: 0
Study 8894569 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem plus vancomycin
Number of subjects: 407
Study 8894569 — intervention group
Group type: COMPARATOR
Intervention: Cefoperazone-sulbactam plus vancomycin
Number of subjects: 407
Study 1643679 — intervention group
Group type: EXPERIMENTAL
Intervention: meperidine 0.25 mg.kg‐1
Number of subjects: 61
Study 1643679 — intervention group
Group type: EXPERIMENTAL
Intervention: meperidine 0.5 mg.kg‐1
Number of subjects: 61
Study 1643679 — intervention group
Group type: EXPERIMENTAL
Intervention: pancuronium 0.06 mg.kg‐1 intravenously
Number of subjects: 61
Study 1643679 — intervention group
Group type: COMPARATOR
Intervention: shivering group
Number of subjects: 61
Study 6426931 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg valerian (1 capsule Harmonicum Much)
Number of subjects: 11
Study 6426931 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg valerian (2 capsules Harmonicum Much)
Number of subjects: 11
Study 6426931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30941800 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory diet (low in processed carbohydrates and animal proteins, rich in omega-3 fatty acids, vitamin C, vitamin D, antioxidants, plant nitrates, and fibres for 4 weeks)
Number of subjects: 30
Study 30941800 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory diet
Number of subjects: 30
Study 30941800 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary change)
Number of subjects: 30
Study 28940840 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2963016 (LY IGlar) at 0.3 U/kg
Number of subjects: 24
Study 28940840 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2963016 (LY IGlar) at 0.6 U/kg
Number of subjects: 24
Study 28940840 — intervention group
Group type: COMPARATOR
Intervention: Lantus (IGlar) at 0.3 U/kg
Number of subjects: 24
Study 28940840 — intervention group
Group type: COMPARATOR
Intervention: Lantus (IGlar) at 0.6 U/kg
Number of subjects: 24
Study 26575111 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS + low-dose transdermal estradiol (TDE) gel (0.06% containing 0.75 mg of TDE, administered once daily for 50 days)
Number of subjects: 38
Study 26575111 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS + low-dose transdermal estradiol (TDE) gel
Number of subjects: 38
Study 26575111 — intervention group
Group type: COMPARATOR
Intervention: LNG-IUS alone (control)
Number of subjects: 38
Study 25185362 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqibushenhuoxue decoction plus Seretide
Number of subjects: 70
Study 25185362 — intervention group
Group type: COMPARATOR
Intervention: Seretide only
Number of subjects: 70
Study 21111754 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention based on the Health Behavior Framework
Number of subjects: 432
Study 19578018 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy for idiopathic unilateral macular hole
Number of subjects: 42
Study 19578018 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline interocular disparities lower than 0.35 degrees at 1 degree eccentricity
Number of subjects: 42
Study 17409778 — intervention group
Group type: EXPERIMENTAL
Intervention: Perichondrium/cartilage island flap technique using full-thickness cartilage disk
Number of subjects: 0
Study 17409778 — intervention group
Group type: EXPERIMENTAL
Intervention: Perichondrium/cartilage island flap technique using bisected cartilage to half of its thickness
Number of subjects: 0
Study 15048552 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate
Number of subjects: 8
Study 15048552 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate
Number of subjects: 8
Study 12814339 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol + acitretin combination therapy
Number of subjects: 60
Study 12814339 — intervention group
Group type: COMPARATOR
Intervention: Acitretin monotherapy
Number of subjects: 60
Study 9664948 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 33
Study 9664948 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 33
Study 8018618 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin (GnRH-agonist)
Number of subjects: 71
Study 8018618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 2501801 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupenthixol dihydrochloride (1 to 2 mg/day)
Number of subjects: 72
Study 2501801 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine maleate (100 to 200 mg/day)
Number of subjects: 72
Study 576832 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproterol (Bronchospasmin) - i.v. 60 and 90 mug, single peroral administration of 20 mg, long-term therapy with 60 mg in either 3 or 6 daily doses
Number of subjects: 0
Study 576832 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30794310 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadir epiglottic pressure during respiratory events in NREM stage 2 sleep terminated with arousals
Number of subjects: 31
Study 28755774 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational computer intervention (MAPIT)
Number of subjects: 316
Study 28755774 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person motivational interviewing (MI)
Number of subjects: 316
Study 28755774 — intervention group
Group type: COMPARATOR
Intervention: Standard probation intake (SAU)
Number of subjects: 316
Study 28755774 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use
Number of subjects: 316
Study 26318552 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation of the calf muscles for 1 hour session twice daily for the first postoperative week
Number of subjects: 40
Study 26318552 — intervention group
Group type: COMPARATOR
Intervention: Current standard of care (control group)
Number of subjects: 40
Study 24492904 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 32
Study 24492904 — intervention group
Group type: EXPERIMENTAL
Intervention: General Supportive Intervention
Number of subjects: 32
Study 24492904 — intervention group
Group type: COMPARATOR
Intervention: No Treatment (Control)
Number of subjects: 32
Study 21788224 — intervention group
Group type: EXPERIMENTAL
Intervention: Pagibaximab 90 mg/kg
Number of subjects: 88
Study 21788224 — intervention group
Group type: EXPERIMENTAL
Intervention: Pagibaximab 60 mg/kg
Number of subjects: 88
Study 21788224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 19470769 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronomodulated infusion of 5-fluorouracil, leucovorin, and oxaliplatin
Number of subjects: 130
Study 19470769 — intervention group
Group type: COMPARATOR
Intervention: Conventional infusion of 5-fluorouracil, leucovorin, and oxaliplatin
Number of subjects: 130
Study 16753318 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized N-acetylcysteine (NAC)
Number of subjects: 19
Study 16753318 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 19
Study 15269349 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic antagonist propranolol administered at encoding
Number of subjects: 0
Study 15269349 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional verbal stimuli
Number of subjects: 0
Study 15269349 — intervention group
Group type: COMPARATOR
Intervention: Neutral verbal stimuli
Number of subjects: 0
Study 11677004 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate daily exercise program (n=14)
Number of subjects: 25
Study 11677004 — intervention group
Group type: COMPARATOR
Intervention: No physical activity beyond usual daily requirements (n=11)
Number of subjects: 25
Study 9919444 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-tracking
Number of subjects: 217
Study 9919444 — intervention group
Group type: COMPARATOR
Intervention: Control (no fast-tracking)
Number of subjects: 217
Study 8050232 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior cruciate ligament retained knee
Number of subjects: 28
Study 8050232 — intervention group
Group type: COMPARATOR
Intervention: Posterior cruciate ligament excised knee
Number of subjects: 28
Study 8050232 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair activity (ascend/descend with one leg at a time)
Number of subjects: 28
Study 8050232 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair activity (using each leg in sequence)
Number of subjects: 28
Study 1867167 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% phosphoric acid gel for 60 seconds
Number of subjects: 40
Study 1867167 — intervention group
Group type: COMPARATOR
Intervention: 60% phosphoric acid gel with 0.5% sodium fluoride for 60 seconds
Number of subjects: 40
Study 418745 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg diethylcarbamazine daily for five months
Number of subjects: 88
Study 418745 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg diethylcarbamazine daily for five months
Number of subjects: 88
Study 418745 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg diethylcarbamazine daily for seven weeks
Number of subjects: 88
Study 30381997 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral rTMS (4000 left‐sided excitatory pulses, 1000 right‐sided inhibitory pulses) for 20 sessions
Number of subjects: 15
Study 30381997 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 15
Study 27842954 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral wedge insole (6 mm)
Number of subjects: 20
Study 27842954 — intervention group
Group type: COMPARATOR
Intervention: Control (without lateral wedge insole)
Number of subjects: 20
Study 26034151 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg once weekly
Number of subjects: 59
Study 26034151 — intervention group
Group type: COMPARATOR
Intervention: Etanercept 50 mg once weekly
Number of subjects: 59
Study 23733374 — intervention group
Group type: EXPERIMENTAL
Intervention: Be Fit Be Well program (2-year moderate intensity weight loss and blood pressure control intervention)
Number of subjects: 365
Study 23733374 — intervention group
Group type: EXPERIMENTAL
Intervention: Be Fit Be Well program
Number of subjects: 365
Study 23733374 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 365
Study 21594216 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mm short implants
Number of subjects: 30
Study 21594216 — intervention group
Group type: COMPARATOR
Intervention: 10 mm long implants in augmented bone
Number of subjects: 30
Study 19015346 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole pretreatment
Number of subjects: 12
Study 19015346 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole pretreatment
Number of subjects: 12
Study 19015346 — intervention group
Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 12
Study 17210593 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa, maximum dosage >100 IU/kg/week during stabilization phase
Number of subjects: 93
Study 17210593 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin dosage
Number of subjects: 93
Study 17210593 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidentified patient characteristics
Number of subjects: 93
Study 17210593 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age, higher BMI, anaemia, ACE inhibitor/ARB use, diabetes as primary cause of kidney disease
Number of subjects: 93
Study 15473502 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30
Number of subjects: 101
Study 15473502 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective Significance Questionnaire (SSQ)
Number of subjects: 101
Study 15473502 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between SSQ ratings and QLQ-C30 change scores
Number of subjects: 101
Study 11036840 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent cyclical etidronate therapy
Number of subjects: 5
Study 9358616 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma rich in HIV antibodies
Number of subjects: 0
Study 9358616 — intervention group
Group type: COMPARATOR
Intervention: Standard seronegative plasma
Number of subjects: 0
Study 8252505 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin plus flutamide
Number of subjects: 327
Study 3888312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSP) (n = 36)
Number of subjects: 75
Study 3888312 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) (n = 39)
Number of subjects: 75
Study 3888312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSP)
Number of subjects: 75
Study 3888312 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 75
Study 31558450 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise (3 sessions per week)
Number of subjects: 50
Study 31558450 — intervention group
Group type: COMPARATOR
Intervention: Concentric exercise (5 sessions per week)
Number of subjects: 50
Study 31558450 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 50
Study 28503827 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument-mounted wide-field white light clinical interferometry
Number of subjects: 22